Brief: Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors
27/03/2025 20:55
March 27 (Reuters) - Sensei Biotherapeutics Inc SNSE.O: SENSEI BIOTHERAPEUTICS REPORTS FAVORABLE PRELIMINARY DOSE EXPANSION DATA FOR SOLNERSTOTUG IN PD-(L)1 RESISTANT TUMORS SENSEI BIOTHERAPEUTICS INC: EARLY DATA SUGGEST SOLNERSTOTUG MAY PROVIDE A MEANINGFUL CLINICAL BENEFIT IN SELECT TUMOR TYPES Source text: ID:nGNX5rXVZx Further company coverage: SNSE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
Faeth Therapeutics rises after FDA grants fast-track status for cancer drug
Brief: Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer
Brief: Faeth Therapeutics Strengthens Executive Team With Senior Leadership Appointments